Table 4 Subgroup analysis by mode of administration and indication for IGRT

Patient characteristics at baseline

n = 71

n = 54

n = 61^a

n = 64^b

 Age, median (range)

66 (28–83)

63 (19–82)

57 (19–79)

69 (48–83)

 Sex, n (%)

  Female

44 (62.0)

39 (72.2)

47 (77.0)

36 (56.3)

  Male

27 (38.0)

15 (27.8)

14 (23.0)

28 (43.8)

 Mode of administration, n (%)

  Infusion pump

71 (100)

0

33 (54.1)

38 (59.4)

  Manual

0

54 (100)

28 (45.9)

26 (40.6)

 Indication for IGRT, n (%)

  PID^a

33 (46.5)

28 (51.9)

61 (100)

0

  SID^b

38 (53.5)

26 (48.1)

0

64 (100)

Infusion and dosing parameters at 12 months^c

n = 65

n = 42^d

n = 52

n = 55

 Infusion volume/infusion, median (IQR), ml

43 (40–60)

30 (20–40)

40 (25–50)

40 (35–50)

 Infusion duration, median (IQR), minutes

60 (45–73)

24 (10–40)

43 (20–65)

60 (40–65)

 Number of infusion sites/infusion, median (IQR)

2 (2–3)

2 (1–2)

2 (2–4)

2 (2–3)

  1 site, n (%)

1 (1.7)

9 (33.3)

8 (18.6)

2 (4.5)

  2 sites, n (%)

32 (53.3)

17 (63.0)

21 (48.8)

28 (63.6)

  3 sites, n (%)

16 (26.7)

0

3 (7.0)

13 (29.5)

  > 3 sites, n (%)

11 (18.3)

1 (3.7)

11 (25.6)

1 (2.3)

 Number of infusions/month/patient, median (IQR)

4 (4–4)

4 (4–8)

4 (4–8)

4 (4–4)

 Maximal infusion rate/site, median (IQR), (ml/h)^e

40.0 (34.0–59.0)

–

33.5 (25.7–40.0)

40.0 (35.0–60.0)

 Weekly dose, median (IQR), g

8.0 (6.0–10.0)

8.0 (6.0–8.0)

9.0 (7.0–12.0)

8.0 (6.0–10.0)

 Dosing interval, n (%)

  Daily

0

0

0

0

  2–6 times/week

2 (3.1)

17 (40.5)

15 (28.8)

4 (7.4)

  Once weekly

56 (87.5)

25 (59.5)

34 (65.4)

47 (87.0)

  Every 2 weeks

4 (6.3)

–

2 (3.8)

2 (3.7)

  Other

2 (3.1)

–

1 (1.9)

1 (1.9)

 IgG trough levels, g/l

  Median (IQR)

8.6 (7.9–10.6)

9.1 (8.3–11.0)

9.9 (8.6–11.8)

8.3 (7.9–9.0)

  Range

3.6–14.5

5.6–13.4

3.6–13.4

5.6–14.5